Essential Site Maintenance: Authorea-powered sites will be updated circa 15:00-17:00 Eastern on Tuesday 5 November.
There should be no interruption to normal services, but please contact us at [email protected] in case you face any issues.

loading page

Autophagy-targeting nanomedicine: strike at the heart of the cancer via precise modulation of autophagy
  • +7
  • Zhouyi Sun,
  • Huali Zuo,
  • Kai Zhang,
  • yang liu,
  • qianwen Wang,
  • qitao Hu,
  • jiwei Qian,
  • bo Zhang,
  • weiyu Chen,
  • zhe Tang
Zhouyi Sun
Author Profile
qianwen Wang
Author Profile
jiwei Qian
Author Profile
weiyu Chen

Corresponding Author:[email protected]

Author Profile

Abstract

Autophagy is a process of engulfing cytoplasmic proteins or organelles, thereby fulfilling cells’ metabolic needs and the renewal of specific organelles. Given its key roles in tumor progression, autophagy has attracted tremendous attention in cancer therapies. Notably, there is a megatrend to integrating autophagy regulation into mainstream treatments. This review focuses on autophagy-targeting nanomedicine (ApT-NM) to modulate autophagy in tumor therapy, including the unmodified and functionalized nanoparticles that target tumors by carrying autophagy modulators. On the one hand, it can reverse treatment resistance by inhibiting protective autophagy, and on the other hand, it can promote the death of cancer cells through type II apoptosis by inducing autophagy. Moreover, advanced nanoplatforms combining various treatments (such as chemotherapy, radiotherapy, photothermal therapy, and photodynamic therapy, etc.) have also been summarized. Last, the future perspectives and directions for ApT-NM research are provided, hoping to emphasize this rising filed and promote the development of ApT-NM.
Submitted to Exploration
19 Sep 2024Review(s) Completed, Editorial Evaluation Pending
26 Sep 2024Editorial Decision: Revise Minor
07 Oct 20241st Revision Received
15 Oct 2024Submission Checks Completed
15 Oct 2024Assigned to Editor
15 Oct 2024Reviewer(s) Assigned
24 Oct 2024Review(s) Completed, Editorial Evaluation Pending